Ha. I have been trading biotechs for awhile. I don't claim to be a good investor like some of you all are With technical analysis etc. however I think we are in agreement on most aspects. I will say I know more about amrn then any other stock I've ever traded or will probably trade in the future. This is a once in a lifetime drug for many reasons but what I like most is the insight gained from The Jelis study. This should put confidence in investors among many other things. I agree epanova sucks. I agree vascepa is massively undervalued.
Market Data 
Markets 
AI
